Peter Guenter - Merck CEO Board
MRK Stock | EUR 167.80 0.20 0.12% |
Insider
Peter Guenter is CEO Board of Merck Company
Age | 61 |
Phone | 49 6151 72 0 |
Web | https://www.merckgroup.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Karla Lewis | Reliance Steel Aluminum | 57 | |
Angel Naveiras | Meli Hotels International | ||
Therese Holm | Norsk Hydro ASA | N/A | |
Lourdes Ripoll | Meli Hotels International | N/A | |
Arthur Ajemyan | Reliance Steel Aluminum | 47 | |
Peter Larocque | SYNNEX | 61 | |
Dag Sigurd | SIVERS SEMICONDUCTORS AB | 73 | |
Stephane Baos | Meli Hotels International | N/A | |
Arvid Moss | Norsk Hydro ASA | 65 | |
Stephen Koch | Reliance Steel Aluminum | 56 | |
Hilde Aasheim | Norsk Hydro ASA | 65 | |
Andr Gerondeau | Meli Hotels International | N/A | |
Vandy Lupton | Reliance Steel Aluminum | N/A | |
Suzanne Bonner | Reliance Steel Aluminum | 48 | |
Bjorn Norrbom | SIVERS SEMICONDUCTORS AB | 72 | |
Patric Erlandsson | SIVERS SEMICONDUCTORS AB | 51 | |
Sean Mollins | Reliance Steel Aluminum | 44 | |
John Thuestad | Norsk Hydro ASA | 63 | |
Robert Green | SIVERS SEMICONDUCTORS AB | 60 | |
Liz Morali | SYNNEX | N/A | |
Michael Urban | SYNNEX | 58 |
Management Performance
Return On Equity | 0.14 | |||
Return On Asset | 0.0656 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director | ||
Matthias Heinzel, CEO Board | ||
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
Gerhard Schmitz, Head Accounting | ||
Christine Seidman, Independent Director | ||
Kathy Warden, Independent Director | ||
Constantin Fest, Head Relations | ||
Paul Rothman, Independent Director | ||
Mary Coe, Independent Director | ||
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
Peter Guenter, CEO Board | ||
Barbara Weiland, Chief Officer | ||
Belen MD, Chair CEO | ||
Marcus Kuhnert, CFO Board | ||
Peter Wendell, Independent Director | ||
Friederike Rotsch, Group Compliance | ||
Leslie Brun, Lead Independent Director | ||
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
Inge Thulin, Independent Director | ||
Dirk Toepfer, Chief Officer | ||
Pamela Craig, Independent Director | ||
Patricia Russo, Independent Director | ||
Franklin Clyburn, Executive Vice President Chief Commercial Officer | ||
Rita Karachun, Senior Vice President - Finance, Global Controller | ||
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
Kai Beckmann, CEO Board | ||
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
Thomas Cech, Independent Director | ||
Michael Nally, Executive Vice President, Chief Marketing Officer | ||
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.14 | |||
Return On Asset | 0.0656 | |||
Profit Margin | 0.16 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 87.36 B | |||
Shares Outstanding | 129.24 M | |||
Shares Owned By Institutions | 60.26 % | |||
Price To Earning | 36.46 X | |||
Price To Book | 2.77 X | |||
Price To Sales | 3.80 X |
Currently Active Assets on Macroaxis
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |